Abstract
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have